68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.

• Age greater than or equal to 18 years.

• Able and willing to follow instructions and comply with the protocol.

• Provide written informed consent prior to participation in the study.

• Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor

Locations
Other Locations
Canada
Foothills Medical Center 1403 29 St NW
RECRUITING
Calgary
Time Frame
Start Date: 2023-02-01
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 500
Treatments
68Ga-HA-DOTATATE
68Ga-HA-DOTATATE Intravenous injection of 100-250 MBq 68Ga-HA-DOTATATE
Related Therapeutic Areas
Sponsors
Leads: Alberta Health services

This content was sourced from clinicaltrials.gov